Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE)

​With partners in various European countries, this intervention study focuses on optimising current treatments in schizophrenia and exploring novel therapeutic options for schizophrenia.

Despite nearly fifty years of pharmacological and psychosocial research, the overall prognosis of schizophrenia has improved only marginally. While the efficacy of most antipsychotic medication is generally uncontested, their overall functional impact has been modest.

This disappointing fact may be attributable to three major issues: first, a considerable minority of patients still does not respond sufficiently to current treatments; second, patients who do respond to medication often discontinue it and relapse; finally, even patients who do respond well to treatment and do adhere to it, continue to suffer from substantial cognitive and functional deficits severely limiting their potential.

In order to improve this unsatisfactory result, this study aims to optimize current treatments in schizophrenia and explore novel therapeutic options for schizophrenia. The study comprises a medication intervention part, a psychosocial intervention part, a biological predictor part and an MRI part.

Inclusion began in 2011 and the study is expected to conclude in 2017.